503417-34-3

Usage

Uses

Used in Medicinal Chemistry:
1-(3-(TRIFLUOROMETHYL)PHENYL)CYCLOPROPANAMINE is used as a building block for the development of novel drug candidates due to its unique structural features that can be leveraged in the design and synthesis of pharmaceuticals.
Used in Drug Development:
In the pharmaceutical industry, 1-(3-(TRIFLUOROMETHYL)PHENYL)CYCLOPROPANAMINE is utilized as a key intermediate in the synthesis of new drugs, taking advantage of its enhanced lipophilicity and metabolic stability imparted by the trifluoromethyl group, as well as the conformational constraints provided by the cyclopropane ring to optimize pharmacokinetic properties.
Further research and exploration of 1-(3-(TRIFLUOROMETHYL)PHENYL)CYCLOPROPANAMINE may reveal additional applications across various fields, as its structural attributes could offer innovative solutions in drug discovery and therapeutic development.

InChI:InChI=1/C10H10F3N/c11-10(12,13)8-3-1-2-7(6-8)9(14)4-5-9/h1-3,6H,4-5,14H2

Upstream product

• 368-77-4 3-trifluoromethylbenzonitrile 
• 557-20-0 diethylzinc 
• 1108698-58-3 1-(3-(trifluoromethyl)phenyl)cyclopropane-1-amine hydrochloride 
• 925-90-6 ethylmagnesium bromide 

Downstream Products

• 1109229-86-8 N-[(1S,2R)-1-benzyl-2-hydroxy-3-({1-[3-(trifluoromethyl)phenyl]cyclopropyl}amino)propyl]-1-oxo-2-(1-propylbutyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide hydrochloride 
• 1109229-80-2 N-[(1S,2R)-1-benzyl-2-hydroxy-3-({1-[3-(trifluoromethyl)phenyl]cyclopropyl}amino)propyl]-1-oxo-2-(1-propylbutyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide 

Relevant academic research and scientific papers

Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in Plasmodium falciparum

Malaria control programs continue to be threatened by drug resistance. To identify new antimalarials, we conducted a phenotypic screen and identified a novel tetrazole-based series that shows fast-kill kinetics and a relatively low propensity to develop h

NOVEL POTASSIUM CHANNEL INHIBITORS

The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.

Tricyclic Compounds As mPGES-1 Inhibitors

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

1,2,3,4-TETRAHYDROPYRROLO[1,2-A]PYRAZINE-6-CARBOXAMIDE AND 2,3,4,5-TETRAHYDROPYRROLO[1,2-a][1,4]-DIAZEPINE-7-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

The present invention relates to derivatives of 1,2,3,4-tetrahydropyrrolo-[1,2-a]pyrazine-6-carboxamides and of 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]diazepine-7-carboxamides, to the preparation thereof and to the therapeutic use thereof.

Primary 1-Arylcyclopropylamines from aryl cyanides with diethylzinc and titanium alkoxides

(Matrix presented) 1-Aryl-substituted primary cyclopropylamines are conveniently prepared from aromatic nitriles and diethylzinc. The yields range from 40 to 56% for donor-substituted (five examples) to 62-82% for non- and acceptor-substituted substrates